The study found that the rodents that had this knockout gene displayed increased levels of obesity, decreased libido, and an inability to copulate
It could improve cardiometabolic outcomes at scale in a country carrying one of the worlds largest burdens of obesity and type 2 diabetes
The GLP-1 CVD outcome trials a) Elixa (Lexisenatide) b) Leader (Liraglutide) c) Sustain-6 (Semaglutide) d) Exscel (Weekly Exenatide) e) Harmony (Albiglutide) f) Rewind (Dulaglutide) g) Pioneer 6 (Oral Semaglutide) Elixa Study (Evaluation of Lixisenatide) In ELIXA, the investigational GLP-1 receptor agonist, lixisenatide, neither reduced nor increased cardiovascular events compared with placebo
You started ipamorelin a few days ago, expecting smooth sailing based on everything you read about its clean side effect profile
Random glucose GWAS in 493,036 individuals provides insights into diabetes pathophysiology, complications and treatment stratification